In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
Californian CNS specialist Alto Neuroscience has completed a $45 million series C financing round led by InVivium Capital. 24 November 2023
Biotechnology
Germany-headquartered contract research organization (CRO) ProtaGene today announced additional investment from Ampersand Capital Partners. 24 November 2023
Pharmaceutical
AstraZeneca recently announced its strategy for the cardiometabolic market, in particular treating obesity and its comorbidities. 24 November 2023
Pharmaceutical
Chinese biopharma Everest Medicines has won approval from China's National Medical Products Administration (NMPA) for Nefecon (budesonide) for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. 24 November 2023
Pharmaceutical
British pharma major AstraZeneca has in-licensed a KRAS blocker, currently codenamed UA022, from Chinese biotech Usynova. 24 November 2023
Biotechnology
Japan’s Chugai Pharmaceuticals revealed that it has now launched its Phesgo, a subcutaneous injection combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase. 24 November 2023
Biotechnology
Following the conclusion of International Gaucher Disease Awareness Month, key opinion leaders (KOLs) interviewed believe pipeline gene therapies will significantly impact the Gaucher disease landscape. 24 November 2023
Biotechnology
New York-based pharma major Pfizer has announced the UK approval of its respiratory syncytial virus (RSV) vaccine Abrysvo (respiratory syncytial virus vaccine). 23 November 2023
Biotechnology
A new center for the manufacturing of advanced medicines is set to be built in Scotland after a multi-million-pound fund was announced in the UK government’s Autumn Statement on Wednesday. 23 November 2023
Biotechnology
The European Commission has granted approval for the label expansion of Kaftrio (ivacaftor/tezacaftor/elexacaftor; marketed in the USA as Trikaftra) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis (CF) ages two through five years old who have at least one F508del mutation in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene, US biopharma Vertex Pharmaceuticals announced today. 23 November 2023
Pharmaceutical
The ongoing conflict involving Israelis and Palestinians represents a long-term threat to the peace and stability of the Middle East, but it is also impacting the production and flow of medicines and other medical supplies in the region, writes The Pharma Letter’s local correspondent. 23 November 2023
Biotechnology
Janssen says it has submitted a type II extension of indication application to the European Medicines Agency (EMA) seeking approval of Rybrevant (amivantamab). 23 November 2023
Biotechnology
Marking its first M&A deal this year, German family-owned pharma major Boehringer Ingelheim has announced the acquisition of T3 Pharmaceuticals. 23 November 2023
Pharmaceutical
Nobody could call it a good week for Bayer, with its shares slumping to their lowest level in a decade on Monday after the firm said it would discontinue a Phase III trial for a blood-thinning drug for heart disease that had failed to demonstrate efficacy. 23 November 2023
Generics
With sales of lucrative immunology medicine Rinvoq (upadacitinib) topping $1 billion in the third quarter, developer AbbVie is taking action to shore up its patent estate. 23 November 2023
Pharmaceutical
The prize for leading the way in the burgeoning obesity market will be one of the richest in pharma. 23 November 2023
Generics
A new partnership in China will see German generics drugmaker Arzneimittel STADA expand and bolster its distribution and promotion of cough and cold brands in the country. 23 November 2023
Biotechnology
Imfinzi (durvalumab), in combination with gemcitabine and cisplatin (chemotherapy), has been recommended for National Health Service (NHS) use in England and Wales for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC) by the National Institute for Health and Care Excellence (NICE). 23 November 2023
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday issued the final guidance COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. 23 November 2023
Pharmaceutical
Jeremy Hunt, the UK’s Chancellor of the Exchequer, yesterday announced as part of his Autumn Statement that the government is making £4.5 billion ($5.6 billion) available in strategic manufacturing sectors - such as auto, aerospace, life sciences and clean energy – from 2025 for five years, with £520 million going to life sciences. 23 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze